AI-driven scientific research firm BioMap has successfully concluded a strategic funding round amounting to hundreds of millions of yuan. This round was co-led by prestigious institutions, including the Shanghai Biomedical Innovation and Transformation Fund, and featured additional investments from Gaorong Capital, among others. Index Capital acted as the exclusive financial advisor for this transaction. The capital raised will be allocated towards refining GeoFlow, BioMap's pioneering microscopic world model tailored for life sciences, as well as propelling the development of its in-house drug development pipeline.
